首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRLF2 |
| Uniprot No | Q9HC73 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-231aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSQGGAAEGVQIQIIYFNLETVQVTWNAS KYSRTNLTFHYRFNGDEAYDQCTNYLLQEGHTSGCLLDAEQRDDILYFSI RNGTHPVFTASRWMVYYLKPSSPKHVRFSWHQDAVTVTCSDLSYGDLLYE VQYRSPFDTEWQSKQENTCNVTIEGLDAEKCYSFWVRVKAMEDVYGPDTY PSDWSEVTCWQRGEIRDACAETPTPPKPKLSK |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural and Functional Characterization of the CRLF2 Complex in Hematopoietic Malignancies"**
- *Authors: Roberts KG, et al.*
- 摘要：研究解析了CRLF2与IL7Rα的异源二聚体结构，揭示了其在儿童急性淋巴细胞白血病中的异常激活机制及JAK-STAT信号通路调控作用。
2. **"CRLF2 Overexpression Drives Proliferation in B-cell Acute Lymphoblastic Leukemia via JAK2 Signaling"**
- *Authors: Yoda A, et al.*
- 摘要：通过重组CRLF2蛋白实验，证实其过表达通过激活JAK2-STAT5通路促进白血病细胞增殖，为靶向治疗提供依据。
3. **"Recombinant CRLF2 Extracellular Domain Inhibits Leukemia Progression in Mouse Models"**
- *Authors: Chen IM, et al.*
- 摘要：开发了CRLF2胞外区重组蛋白，证明其能竞争性抑制配体结合，减少下游信号传导，显著延缓白血病小鼠模型肿瘤生长。
4. **"CRLF2 Rearrangements in Down Syndrome-associated ALL: Expression and Therapeutic Targeting"**
- *Authors: Hertzberg L, et al.*
- 摘要：分析了CRLF2重组蛋白在唐氏综合征相关白血病中的表达特征，并评估了针对CRLF2/JAK2复合物的单克隆抗体疗法的体外效果。
CRLF2 (cytokine receptor-like factor 2), also known as thymic stromal lymphopoietin receptor (TSLPR), is a type I cytokine receptor that plays a critical role in immune signaling. It pairs with the interleukin-7 receptor alpha chain (IL-7Rα) to form a functional receptor complex for thymic stromal lymphopoietin (TSLP), a cytokine involved in T helper 2 (Th2)-mediated immune responses. TSLP signaling through the CRLF2/IL-7Rα complex activates downstream pathways like JAK-STAT, MAPK, and PI3K, driving inflammatory processes in allergic diseases, asthma, and certain cancers. Dysregulation of CRLF2 expression is linked to pathological conditions, including lymphoid malignancies (e.g., B-cell acute lymphoblastic leukemia) and autoimmune disorders.
Recombinant CRLF2 proteins are engineered versions of the receptor, typically produced in mammalian or insect cell systems to ensure proper post-translational modifications and structural integrity. These proteins are purified using affinity chromatography and validated for functionality through binding assays (e.g., TSLP ligand interaction) and activity tests in cellular models. Recombinant CRLF2 serves as a vital tool for studying TSLP-mediated signaling mechanisms, screening therapeutic agents targeting the TSLP/CRLF2 axis, and developing diagnostic assays. In therapeutic contexts, blocking CRLF2 or its signaling pathway has emerged as a strategy to mitigate inflammation in allergies or curb proliferation in CRLF2-overexpressing cancers. Research continues to explore its role in disease pathogenesis and its potential as a biomarker or drug target.
×
